Yves Denoux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yves Denoux has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
H Crouet
2 shared publicationsJ J Voigt
2 shared publicationsJ Simony-Lafontaine
2 shared publications- Jacques Chasle
Department of Pathology, Centre François Baclesse, 14076 Caen, France
2 shared publications V Boute
2 shared publicationsA Balaton
1 shared publication
Latest Publications
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 605
Prognostic and predictive value of HER2, PR, ER, and KI67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel
605 Background: To define the value of biopathological parameters as prognostic and predictive markers in patients (pts) with node positive, operable breast cancer involved in the phase III trial PACS 01. Methods: We retrospectively analyzed the prognostic value of ER, PR, HER2, and Ki-67, in 1190 patients with primary operable node positive breast cancer patients treated with either Arm A: 6 cycles of FEC100 (595 pts) or arm B: docetaxel 100 mg/m replaced FEC100 for the last 3 cycles (595 pts), extracted from the data base of 1999 pts enrolled in PACS01 trial. This subgroup was similar to the whole population of the trial in terms of age, node involvement, and ER positivity. A panel of pathologists centrally and blindly reviewed the cases. All four markers were tested by immunohistochemistry centrally. Results were correlated to clinical out come at a median follow up of 59.7 months (SABCS 2004). Results: Using 5 years of follow-up data, we showed i) for arm B, a better DFS: unadjusted log rank (log) p =0,023 and OS: log p=0.015, ii) an association between HER2 overexpression and/or amplification (DFS: log p =.0002; OS log p<.0001), high Ki-67 (DFS: log p <0.0001; OS: log p <0.0001) and worse outcome. ER+ /PR + and ER-/PR+ pts had a better outcome than pts whose tumors were ER-/PR-or ER+/PR- (p<0.001 for both). Her2 positivity was not a poor prognosis factor for pts in arm B which is suggesting its role as a putative predictive factor of response to sequential treatment. Conclusion: This retrospective investigation demonstrated that HER2, PR, ER, and Ki-67 expressions had significant prognostic value for N+ patients. Furthermore, HER2 could be used to discern groups of individuals who could benefit from the use of sequential chemotherapy with anthracycline and docetaxel. More results will be presented at the meeting. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 605
Prognostic and predictive value of HER2, PR, ER, and KI67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel
605 Background: To define the value of biopathological parameters as prognostic and predictive markers in patients (pts) with node positive, operable breast cancer involved in the phase III trial PACS 01. Methods: We retrospectively analyzed the prognostic value of ER, PR, HER2, and Ki-67, in 1190 patients with primary operable node positive breast cancer patients treated with either Arm A: 6 cycles of FEC100 (595 pts) or arm B: docetaxel 100 mg/m replaced FEC100 for the last 3 cycles (595 pts), extracted from the data base of 1999 pts enrolled in PACS01 trial. This subgroup was similar to the whole population of the trial in terms of age, node involvement, and ER positivity. A panel of pathologists centrally and blindly reviewed the cases. All four markers were tested by immunohistochemistry centrally. Results were correlated to clinical out come at a median follow up of 59.7 months (SABCS 2004). Results: Using 5 years of follow-up data, we showed i) for arm B, a better DFS: unadjusted log rank (log) p =0,023 and OS: log p=0.015, ii) an association between HER2 overexpression and/or amplification (DFS: log p =.0002; OS log p<.0001), high Ki-67 (DFS: log p <0.0001; OS: log p <0.0001) and worse outcome. ER+ /PR + and ER-/PR+ pts had a better outcome than pts whose tumors were ER-/PR-or ER+/PR- (p<0.001 for both). Her2 positivity was not a poor prognosis factor for pts in arm B which is suggesting its role as a putative predictive factor of response to sequential treatment. Conclusion: This retrospective investigation demonstrated that HER2, PR, ER, and Ki-67 expressions had significant prognostic value for N+ patients. Furthermore, HER2 could be used to discern groups of individuals who could benefit from the use of sequential chemotherapy with anthracycline and docetaxel. More results will be presented at the meeting. No significant financial relationships to disclose.
- 1 December 2003
- Vol. 23 (6) , 597-600
[Diabetic mastopathy].
This report concerns a case of diabetic mastopathy, a benign but pseudotumoral clinicopathologic entity which occurs in young women with type 1 diabetes. Positive diagnosis, differential diagnosis and literature data are discussed.
- 1 December 2003
- Vol. 23 (6) , 597-600
[Diabetic mastopathy].
This report concerns a case of diabetic mastopathy, a benign but pseudotumoral clinicopathologic entity which occurs in young women with type 1 diabetes. Positive diagnosis, differential diagnosis and literature data are discussed.
- 1 December 2003
- Vol. 23 (6) , 617-22
[HER2 gene amplification assay: is CISH an alternative to FISH?].
The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.
- 1 December 2003
- Vol. 23 (6) , 617-22
[HER2 gene amplification assay: is CISH an alternative to FISH?].
The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.
- 1 June 2003
- Vol. 23 (3) , 266-78
[2002 Standards, Options and Recommendations: good practice for the management and shipment of histological and cytopathological cancer specimens].
The Standards, Options and Recommendations (SOR) collaborative project was initiated in 1993 by the Federation of the French Cancer Centres (FNCLCC), with the 20 French Regional Cancer Centres, several French public university and general hospitals, as well as private clinics and medical speciality societies. Its main objective is the development of serviceable clinical practice guidelines in order to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review, followed by critical appraisal by a multidisciplinary group of experts. Draft guidelines are produced, then validated by specialists in cancer care delivery. Produce clinical practice guidelines for the management and shipment of histological and cytopathological cancer specimens using the methodology developed by the Standards, Options and Recommendations project. The FNCLCC designated the group of experts. Available data were collected by a search of Medline and lists selected by experts in the group. A first draft of the guidelines was written, then validated by independent reviewers. The main recommendations are: 1/ High-quality transmission of information between professionals is essential to the management of cancer specimens in order to assure high-quality diagnosis and evaluation of prognostic factors; 2/ Written procedures concerning sample shipment, handling, storage, registration, tracking and fixation exist; these procedures, as well as the necessary shipping material, will be sent to all clinical services involved; 3/ When possible, fresh, unfractionated, oriented surgical samples will be submitted to the same histological and cytopathological laboratory; 4/ Samples collected for extemporaneous examination, freezing or cell culture must be shipped immediately under appropriate storage conditions; 5/ Once frozen, samples can be stored in a deep freezer at temperatures of -80 degrees C or below, or kept in liquid nitrogen; 6/ Fixing tissues shortly after sample collection is essential to prevent cell lysis; 7/ Computerised systems will be used to assure correct specimen registration and tracking in histological and cytopathological laboratories.
- 1 June 2003
- Vol. 23 (3) , 266-78
[2002 Standards, Options and Recommendations: good practice for the management and shipment of histological and cytopathological cancer specimens].
The Standards, Options and Recommendations (SOR) collaborative project was initiated in 1993 by the Federation of the French Cancer Centres (FNCLCC), with the 20 French Regional Cancer Centres, several French public university and general hospitals, as well as private clinics and medical speciality societies. Its main objective is the development of serviceable clinical practice guidelines in order to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review, followed by critical appraisal by a multidisciplinary group of experts. Draft guidelines are produced, then validated by specialists in cancer care delivery. Produce clinical practice guidelines for the management and shipment of histological and cytopathological cancer specimens using the methodology developed by the Standards, Options and Recommendations project. The FNCLCC designated the group of experts. Available data were collected by a search of Medline and lists selected by experts in the group. A first draft of the guidelines was written, then validated by independent reviewers. The main recommendations are: 1/ High-quality transmission of information between professionals is essential to the management of cancer specimens in order to assure high-quality diagnosis and evaluation of prognostic factors; 2/ Written procedures concerning sample shipment, handling, storage, registration, tracking and fixation exist; these procedures, as well as the necessary shipping material, will be sent to all clinical services involved; 3/ When possible, fresh, unfractionated, oriented surgical samples will be submitted to the same histological and cytopathological laboratory; 4/ Samples collected for extemporaneous examination, freezing or cell culture must be shipped immediately under appropriate storage conditions; 5/ Once frozen, samples can be stored in a deep freezer at temperatures of -80 degrees C or below, or kept in liquid nitrogen; 6/ Fixing tissues shortly after sample collection is essential to prevent cell lysis; 7/ Computerised systems will be used to assure correct specimen registration and tracking in histological and cytopathological laboratories.
- 1 January 2003
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 78 (1) , 23-26
Double immunohistochemical labeling technique applied to different types of cytokeratins in epithelial proliferations of the breast.
The double labeling technique using peroxidase and alkaline phosphatase for immunohistochemistry is well known, but must be adapted according to the antibodies used, fixation, and technical conditions. The technique allows identification on one slide of two antigens that are localized in the same or different cells of the same lesion. The aim of this paper is to describe the adaptation of this technique to cytokeratins of normal mammary tissue and proliferative lesions of the breast.
- 1 January 2003
- Published by Taylor & Francis in Biotechnic & Histochemistry
- Vol. 78 (1) , 23-26
Double immunohistochemical labeling technique applied to different types of cytokeratins in epithelial proliferations of the breast.
The double labeling technique using peroxidase and alkaline phosphatase for immunohistochemistry is well known, but must be adapted according to the antibodies used, fixation, and technical conditions. The technique allows identification on one slide of two antigens that are localized in the same or different cells of the same lesion. The aim of this paper is to describe the adaptation of this technique to cytokeratins of normal mammary tissue and proliferative lesions of the breast.
- 1 April 2001
- Vol. 88 (4) , 419-25
[Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
Ductal carcinoma in situ (DCIS), a non metastazing lesion of the breast is more frequently observed due to the improvement of mammography and widespread use of screening. The most important risk of this disease is local recurrence. In about half of cases, it occurs as an infiltrating carcinoma. In a series of 166 DCIS treated by lumpectomy plus radiotherapy, we have studied clinico-pathological factors for the prognosis of local recurrences and particularly the Van Nuys Index criteria (nuclear grade, necrosis, size, margin width). After median follow up of 75 months, 21 recurrences were observed with 10 corresponding to an infiltrating carcinoma and one of them died. The size of DCIS evaluated on pathological documents (histological slides and shames), the Van Nuys Prognostic Index (VNPI) and the mitotic index were the main prognostic factors of local recurrence. We discuss these results and confront them to a review of the literature focalised on the delicate problem of the decision of conservative treatment. A multidisciplinary approach (Breast : Surgeon, Radiologist, Pathologist and Radiotherapist), a standardisation of pathological criteria (size, margin width) and the continuation of randomised trials are necessary to fine the best attitude of conservative therapy.
- 1 April 2001
- Vol. 88 (4) , 419-25
[Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
Ductal carcinoma in situ (DCIS), a non metastazing lesion of the breast is more frequently observed due to the improvement of mammography and widespread use of screening. The most important risk of this disease is local recurrence. In about half of cases, it occurs as an infiltrating carcinoma. In a series of 166 DCIS treated by lumpectomy plus radiotherapy, we have studied clinico-pathological factors for the prognosis of local recurrences and particularly the Van Nuys Index criteria (nuclear grade, necrosis, size, margin width). After median follow up of 75 months, 21 recurrences were observed with 10 corresponding to an infiltrating carcinoma and one of them died. The size of DCIS evaluated on pathological documents (histological slides and shames), the Van Nuys Prognostic Index (VNPI) and the mitotic index were the main prognostic factors of local recurrence. We discuss these results and confront them to a review of the literature focalised on the delicate problem of the decision of conservative treatment. A multidisciplinary approach (Breast : Surgeon, Radiologist, Pathologist and Radiotherapist), a standardisation of pathological criteria (size, margin width) and the continuation of randomised trials are necessary to fine the best attitude of conservative therapy.
- 1 November 2000
- Vol. 29 (7) , 655-61
[Is mammography useful in Paget's disease of the breast?].
Interest of the mammogram in Paget's disease of the breast, especially for a therapeutic decision in otherwise asymptomatic women with Paget's disease, who would be candidates for conservative treatment. 61 women with histological Paget's disease of the nipple, treated by mastectomy, were retrospectively analyzed with clinical, radiological and pathological correlations. An underlying carcinoma was found in 60 cases (98.4%), atypical epithelial hyperplasia in one. In the 24 women without breast palpable mass, 17 (71%) had a normal mammogram, 12 (50%) had carcinoma with an invasive component, 14 (58%) had a cancer at a distance from the nipple, 17 (71%) had a multifocal carcinoma. All 37 women with a palpable mass had a pathological mammogram, 36 of them had carcinoma with an invasive component, 35 (95%) a cancer at a distance from the nipple, 31 (84%) a multifocal carcinoma. Mammogram is of limited value in management of Paget's disease of the breast for women without breast palpable mass; it can not predict the site of malignancy, nor the invasive component.
- 1 November 2000
- Vol. 29 (7) , 655-61
[Is mammography useful in Paget's disease of the breast?].
Interest of the mammogram in Paget's disease of the breast, especially for a therapeutic decision in otherwise asymptomatic women with Paget's disease, who would be candidates for conservative treatment. 61 women with histological Paget's disease of the nipple, treated by mastectomy, were retrospectively analyzed with clinical, radiological and pathological correlations. An underlying carcinoma was found in 60 cases (98.4%), atypical epithelial hyperplasia in one. In the 24 women without breast palpable mass, 17 (71%) had a normal mammogram, 12 (50%) had carcinoma with an invasive component, 14 (58%) had a cancer at a distance from the nipple, 17 (71%) had a multifocal carcinoma. All 37 women with a palpable mass had a pathological mammogram, 36 of them had carcinoma with an invasive component, 35 (95%) a cancer at a distance from the nipple, 31 (84%) a multifocal carcinoma. Mammogram is of limited value in management of Paget's disease of the breast for women without breast palpable mass; it can not predict the site of malignancy, nor the invasive component.
- 1 August 2000
- Vol. 34 (4) , 266-70
[Atypical prostatic leiomyoma: a new case with cytodensitometric analysis].
Atypical prostatic leiomyoma is a very rare benign tumor. We report here a new case with a cytodensitometric analysis. The result of cytodensitometry is a polyploid tumor that is well correlated with the morphology of nuclear multilobulated cells of this tumor. The differential diagnosis is essentially the leiomyosarcoma which is characterized by the absence of mitotic activity.
- 1 August 2000
- Vol. 34 (4) , 266-70
[Atypical prostatic leiomyoma: a new case with cytodensitometric analysis].
Atypical prostatic leiomyoma is a very rare benign tumor. We report here a new case with a cytodensitometric analysis. The result of cytodensitometry is a polyploid tumor that is well correlated with the morphology of nuclear multilobulated cells of this tumor. The differential diagnosis is essentially the leiomyosarcoma which is characterized by the absence of mitotic activity.